45 results about "Drug withdrawal syndrome" patented technology

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, "aversive" experience in physically dependent addicts (e.g., precipitated abstinence syndrome).

The present invention is directed to the use of ibudilast for treating addictions, including drug and behavioral addictions. In particular, ibudilast is used to diminish the dopamine-mediated reward associated with addictions and to treat withdrawal syndromes after discontinuance of addictive drug use or behavior.

Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, and status epilepticus.

Provided herein are 19-nor C3,3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein, , R¹, R², R^3a, R^3b, R^4a, and R^4b are as defined herein, and A is a carbon bound substituted or unsubstituted 5- to 6-membered heteroaryl ring as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

Dosage regimens of buprenorphine to treat withdrawal or abstinence syndrome in a drug dependent or opioid tolerant patient who is pregnant are described. The method includes treating withdrawal or abstinence syndrome of the patient by transdermal administration of an amount of buprenorphine effective to reduce withdrawal symptoms. For example, a first buprenorphine-containing transdermal dosage form for a second dosing period that is no more than about 5 days, the second dosage form comprising the same or a greater dosage of buprenorphine than the first dosage form; and a third buprenorphine-containing transdermal dosage form for a third dosing period that is at least 2 days, the third dosage form comprising the same or a greater dosage of buprenorphine than the second dosage form.

The instant invention provides potent antiandrogen compounds, such as 3β-acetoxyandrost-1,5-diene-17-ethylene ketal and 3β-hydroxyandrost-1,5-diene-17-ethylene ketal, and methods for their use in the prevention and treatment of biological conditions mediated by androgen receptors. Thus, for example, compounds of the invention are useful in the prevention and treatment of prostrate cancer. Furthermore, it has been discovered that compounds of the invention are useful in the prevention and treatment of androgen-independent cancers such as androgen-independent prostrate cancer. Finally, inventive compounds may be used to treat antiandrogen induced withdrawal syndrome.

Methods of using MIF inhibitors such as those characterized by structure I are disclosed. The MIF inhibitors can be used for treating conditions such as neuropathic pain and its associated symptoms, as well as for treating drug and behavioral addictions, such as opiate dependence. Additionally, MIF inhibitor compounds can be used for treating withdrawal syndromes after discontinuance of addictive drug use or behavior.

Disclosed are compounds having the formula:

where

• • R₁=H, C₁-C₆ alkyl, cycloalkyl,
  • R₂=H, C₁-C₆ alkyl, cycloalkyl
  • W=C_nH_2n-m—NH (n=1-6, m=0, 2, or 4),
  • X=
  • R₃=
  • Y=
  • Z=CONR₈(CH₂)_n, CONR₈(CH₂)_nCO, P(CH₃)OCHR₈OCOR₉, SO₂, SO₂(CH₂)_n, SO₂(CH₂)_nCO, SO₂NR₈(CH₂)_n, SO₂NR₈(CH₂)_nCO, n=1-4
  • R₄=H, (CH₂)_nOH, (CH₂)_nOCOR₁₀, (CH₂)_nNR₁₀R₁₁, (CH₂)_nCONR₁₀R₁₁, n=0-4
  • R₅=H, (CH₂)_nNR₁₂R₁₃, n=0-4
  • R₆=H, (CH₂)_nNR₁₄R₁₅, n=0-4
  • R₇=H, C₁-C₆ alkyl, cycloalkyl; R₈=H, C₁-C₆ alkyl, cycloalkyl; R₉=H, C₁-C₆ alkyl, cycloalkyl;
  • R₁₀=H, C₁-C₆ alkyl, cycloalkyl; R₁₁=H, C₁-C₆ alkyl, cycloalkyl; R₁₂=H, C₁-C₆ alkyl, cycloalkyl;
  • R₁₃=H, C₁-C₆ alkyl, cycloalkyl; R₁₄=H, C₁-C₆ alkyl, cycloalkyl; R₁₅=H, C₁-C₆ alkyl, cycloalkyl.

Dashed lines: optional; conformational constraint by (CH₂)_n, n=1-3, R′=H or O(═) as well as pharmaceuticals compositions and methods for the treatment of opiate addiction, opiate dependence, opiate tolerance, opiate related abstinence syndrome, nicotine addition and obesity based thereon.

Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R¹, R^2a, R^2b, R³, R₄, R^5a, R^5b, R⁶, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R¹, R², R³, and R⁴ are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

The present invention provides compound having the structure and pharmaceutically acceptable salts or derivatives thereof, as well as compositions including such compounds. The invention also provides methods of (1) preventing pain, (2) treating pain, (3) inducing sedation, (4) treating opiate addiction, (5) treating opiate withdrawal (abstinence syndrome) and/or (6) treating cough in a patient in need thereof by administering a compound or composition of the invention.

The invention belongs to the biological gene engineering field, relating to a production method of recombined adenovirus expressing endogenous opioid peptides (Beta-endorphin) and having curative effect to withdrawal syndrome, and a method for curing the withdrawal syndrome by utilizing the recombined adenovirus. The methods can also be used in the gene therapy of other diseases.

A stable freeze-dried powder preparation of tetrodotoxin and the producing method thereof. The freeze-dried powder preparation has tetrodotoxin as the main active ingredient, and comprises solubilizer, excipient and stabilizer. The said solubilizer is citric acid. The excipient is sodium chloride, mannitol or their composite. The stabilizer is dextran, trehalose or their composite. The ratio of tetrodotoxin, excipient and stabilizer is 1:150-3000:50-500 or 50-6000. Preferably, the preparation comprises lidocaine hydrochloride as function modulator. The preparation of the present invention can be used for avoiding the dependent abstinence syndrome of drugs such as opiates and cannabis.

The invention relates to a compound medicine, especially a compound medicine made up of nonopium medicine with biological abstinence of drugs function for curing or releasing 'abstinence syndrome'. The product is mainly made up of flowing ingredients with following weigh proportion: nonopium medicine pain easing medicine 10-80%, choline resisting medicine 0.0001-5%, psychosis resisting medicine 10-80%. The product contains no opium medicine, no addict; it belongs to non-substitute type medicine. It can control the bad symptom when in 'abstinence of drugs'.

Formulations comprising buprenorphine are useful for treating opioid withdrawal syndrome.